Investigacin clnica Estudios en curso : Si bien Ipamrelin se ha mostrado prometedor en estudios preclnicos, sus aplicaciones clnicas an se estn investigando
These will often depend on your dosage, your sensitivity to medication in general, and other factors that could trigger a reaction
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Many are runners, lifters, CrossFitters, or weekend athletes
If you are asymptomatic, we will usually suggest oral supplementation before any injection